Observational study finds significant fat loss and muscle preservation in adults with obesity — Evidence Review

Most weight lost with GLP-1 obesity drugs is primarily from fat, with relative muscle mass largely preserved, according to a new study from a Vienna outpatient clinic. Related studies generally agree that GLP-1 therapies induce substantial fat loss, but the degree of muscle preservation may vary depending on the specific drug and patient factors.

• Meta-analyses indicate that while GLP-1 therapies (especially more potent agents like semaglutide and tirzepatide) are effective for weight loss, they are typically associated with some reduction in lean (muscle) mass, often comprising about 25% or less of total weight lost 3 5.
• Some studies suggest that muscle mass loss with GLP-1 drugs is proportional to overall weight loss and may not translate to clinically significant muscle wasting, with muscle quality potentially improving due to reduced fat infiltration 5.
• The Vienna clinic study’s finding of largely preserved relative skeletal muscle mass aligns with literature showing that muscle loss, when adjusted for fat loss, may not be as pronounced as initially feared, particularly when physical activity is maintained 2 3 5.

Study Overview and Key Findings

With GLP-1 receptor agonists increasingly used for obesity, understanding how these drugs affect body composition is crucial. Concerns have been raised about whether rapid weight loss from these medications could lead to meaningful muscle loss, which may negatively impact health and function. The new study presented at the European Congress on Obesity 2026 addresses this question by examining real-world body composition changes among adults receiving GLP-1–based therapies at a Viennese outpatient clinic, with a focus on separating fat from muscle loss.

Property	Value
Organization	specialized private obesity outpatient clinic in Vienna
Population	Adults with obesity
Sample Size	n=486
Methods	Observational Study
Outcome	Fat mass and skeletal muscle mass changes
Results	Patients lost 9.9% body weight, with 80-85% from fat

The study followed 486 adults with obesity, most of whom received semaglutide, with others on liraglutide or tirzepatide. Using bioelectrical impedance analysis (BIA), researchers tracked absolute and relative changes in fat and muscle mass over multiple time periods. After an average of 14 months, participants lost nearly 10% of their body weight, with 80-85% of this loss attributed to fat. More than 70% preserved or increased their relative skeletal muscle mass, and statistical modeling suggested muscle mass remained stable when adjusted for changes in fat mass. The authors acknowledge limitations, including the retrospective design, missing data, and a predominantly female cohort, and note that long-term effects require further study.

Literature Review: Related Studies

To contextualize these results, we searched the Consensus database, which contains over 200 million research papers, using the following search queries:

1. GLP-1 drugs weight loss fat percentage
2. body composition changes GLP-1 therapy
3. weight loss mechanisms GLP-1 medications

Below, we synthesize related studies by key topics:

Topic	Key Findings
How do GLP-1 drugs impact fat vs. muscle mass during weight loss?	- Most GLP-1–induced weight loss arises from fat, but some reduction in lean mass (typically 15–25% of weight lost) is observed, especially with potent agents 3 5. - Liraglutide may better preserve lean mass compared to semaglutide or tirzepatide 3.
What happens after stopping GLP-1 therapy?	- Discontinuing GLP-1 drugs leads to significant weight regain, often proportional to the initial loss, regardless of lifestyle interventions 2 6. - Exercise during and after therapy can help maintain weight loss and body composition improvements 2.
Are there differences among specific GLP-1 drugs and patient factors?	- Younger, female, non-diabetic patients experience greater weight and fat loss from GLP-1 therapies 4 9. - Semaglutide and tirzepatide are more effective for weight and fat loss, though with higher lean mass reduction risk 3 4.
What are the mechanisms and clinical implications of GLP-1 therapy?	- GLP-1 drugs primarily lower body weight by reducing appetite and food intake via central and peripheral mechanisms 7 8 10. - Improvements in muscle quality and metabolic health may offset the modest muscle loss seen with some GLP-1 treatments 5 7.

How do GLP-1 drugs impact fat vs. muscle mass during weight loss?

The new Vienna study’s finding of predominant fat loss and preserved relative muscle mass aligns with broader evidence that GLP-1 drugs mainly reduce body fat while sparing muscle to a significant extent. Meta-analyses show that lean mass reduction commonly accounts for 15–25% of total weight lost, with some variation depending on the specific drug and patient context 3 5. Liraglutide may be less likely to reduce lean mass than semaglutide or tirzepatide 3, which is consistent with the Vienna study’s observation of muscle preservation when treatment is combined with physical activity advice.

• Most weight lost with GLP-1 drugs is due to fat mass reduction, with lean mass loss typically making up a minority of the total 3 5.
• The extent of muscle loss is generally proportional to the amount of fat lost, rather than indicative of muscle wasting 3.
• Some GLP-1 drugs, such as liraglutide, may better preserve lean mass compared to more potent agents 3.
• Interventions like exercise may further support muscle preservation during GLP-1 therapy 2 5.

What happens after stopping GLP-1 therapy?

Several studies indicate that discontinuing GLP-1 therapy leads to significant weight regain, often returning patients close to their pre-treatment weight, regardless of concurrent lifestyle interventions 6. However, supervised exercise during and after pharmacotherapy can help sustain weight loss and favorable body composition changes, as observed in randomized trials 2. This underscores the importance of chronic or long-term treatment strategies and the integration of physical activity to maintain benefits.

• Weight regain after GLP-1 discontinuation is common and often proportional to initial loss 6.
• Lifestyle interventions alone are typically insufficient to prevent regain after stopping GLP-1 drugs 6.
• Combining pharmacotherapy with exercise leads to better long-term maintenance of weight loss and body composition 2.
• These findings highlight the potential need for ongoing therapy or robust lifestyle support post-treatment 2 6.

Are there differences among specific GLP-1 drugs and patient factors?

Efficacy and body composition effects of GLP-1 therapies can differ based on the specific agent used (e.g., liraglutide, semaglutide, tirzepatide) and patient characteristics. Larger benefits are observed in younger, female, non-diabetic patients, and those with higher baseline weight or BMI 4 9. More potent agents such as semaglutide and tirzepatide induce greater fat and weight loss, but may result in greater lean mass reduction compared to liraglutide 3 4.

• Patient demographics (age, sex, diabetes status) influence the degree of weight and fat loss 4 9.
• Semaglutide and tirzepatide are associated with more robust weight/fat loss, but higher risk of lean mass loss 3 4.
• Liraglutide may be preferable in populations where muscle preservation is a particular concern 3.
• These nuances are important for individualized treatment decisions and risk stratification 3 4.

What are the mechanisms and clinical implications of GLP-1 therapy?

GLP-1 drugs primarily induce weight loss by reducing appetite and caloric intake through actions on central and peripheral pathways 7 8 10. In addition to weight and fat loss, these drugs improve metabolic health, sometimes leading to enhanced muscle quality despite minor reductions in muscle mass. Improvements in insulin sensitivity and reduced muscle fat infiltration may mitigate the risk of clinically relevant muscle dysfunction 5 7.

• GLP-1 therapies act via appetite suppression and altered nutrient absorption, rather than major increases in energy expenditure 7 8 10.
• Improvements in muscle composition and metabolic health may offset small absolute losses in muscle mass 5.
• The safety and efficacy profile of GLP-1 drugs makes them suitable for long-term use in selected patients 7 10.
• Understanding these mechanisms informs both clinical practice and future drug development 7 10.

Future Research Questions

While current evidence generally supports the favorable body composition effects of GLP-1 therapies, several gaps remain. Limitations in study design (e.g., retrospective analyses, short follow-up, lack of diverse populations) and uncertainty about long-term outcomes highlight the need for further investigation into sustained efficacy, optimal patient selection, and strategies to maximize muscle preservation.

Research Question	Relevance
What are the long-term effects of GLP-1 therapy on muscle mass and function?	Long-term data are needed to determine whether muscle mass and function remain stable over years of GLP-1 use, as most studies have short follow-up periods 3 5.
How can exercise be optimized to preserve muscle during GLP-1 therapy?	Combining exercise with GLP-1 drugs may help maintain muscle mass, but the best types, intensity, and timing of exercise interventions remain unclear and warrant further study 2 5.
Are there differences in body composition effects among GLP-1 drugs (e.g. liraglutide, semaglutide, tirzepatide)?	Understanding drug-specific effects could guide personalized therapy, as some agents may have more favorable muscle preservation profiles than others 3 4.
What are the most accurate methods for assessing muscle mass changes during weight loss treatment?	Current methods (e.g., BIA) have limitations; improved, standardized techniques (such as MRI) could yield more reliable data on true muscle versus lean mass changes 5.
How does GLP-1 therapy affect muscle health in older adults or those at risk of sarcopenia?	Older adults may be more susceptible to muscle loss; data specific to this population are sparse but critical for safe prescribing and risk stratification 5.

---

This article provides a comprehensive, evidence-based synthesis of current knowledge on the effects of GLP-1 obesity drugs on body composition, emphasizing the importance of continued research to optimize therapies and outcomes for diverse patient populations.